Santosh Gautam

Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation

Santosh Gautam, Laura Morrison, Philippe Thompson‐Leduc, Avani Samandur et autres

us, ca (code pays fourni par la source)

Front-line treatment approaches in multiple myeloma: real-world data from a community-based oncology network

R. Steve Paulson, Santosh Gautam, Rohan Medhekar, Siraje Mahmud et autres

us, il (code pays fourni par la source)

Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma

Carlyn Tan, Jennifer S. Harper, Santosh Gautam, Alex Z. Fu et autres

us, il (code pays fourni par la source)

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma

Santosh Gautam, Laura Morrison, Philippe Thompson‐Leduc, Bronwyn Moore et autres

us, ca (code pays fourni par la source)

Real-World Characteristics and Outcomes of Patients with Relapsed or Refractory Multiple Myeloma Treated with Talquetamab: Early Results from eMMpower Consortium

Jack Khouri, Rafaël Fonseca, Cindy Varga, Lisa Raff et autres

eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma (MM)

Rafaël Fonseca, Cindy Varga, Baylee Bryan, Jack Khouri et autres

Recent Trends in Real-World Frontline Treatment Patterns and Outcomes for Patients with Multiple Myeloma in the United States

Joshua Richter, Santosh Gautam, Xin Yin, Philippe Thompson‐Leduc et autres

Real-World Safety Outcomes and Healthcare Resource Utilization (HCRU) During Outpatient, Inpatient, and Hybrid Step-up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal): A Chart Review Study

Cindy Varga, Jack Khouri, David Oveisi, Baylee Bryan et autres

Cost per Responder Model of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma

Santosh Gautam, Laura Morrison, Philippe Thompson‐Leduc, Bronwyn Moore et autres

Letter to the Editor regarding ‘Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study’

Rohan Medhekar, Laura Clark, Santosh Gautam, Annelore Cortoos

us, il (code pays fourni par la source)

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis

Lucio Gordan, Rohan Medhekar, Alex Z. Fu, Mostafa Shokoohi et autres

us, ca (code pays fourni par la source)

Cycles of Malnutrition: Intergenerational Health Transmission in India

Santosh Gautam, Timothy J. Halliday, Bhashkar Mazumder

us, ch, de (code pays fourni par la source)